Metabocure
Biopharmaceutical Solutions for Cancer Cachexia
Company Overview
Snapshot
Founded in July 2024 by Ronen Sarusi, MetaboCure operates with 1–10 employees. The company secured a grant in December 2024 from the Israel Innovation Authority.
Business overview
MetaboCure is a biopharmaceutical company focused on developing novel therapies for cancer cachexia and other metabolic complications. The company's core product, Nuforal, is an HNF4α mRNA/LNP-based drug designed to restore HNF4α levels in the liver, which are suppressed during cachexia. By addressing this suppression, MetaboCure aims to reverse symptoms like weight loss and muscle wasting, improve clinical outcomes, and shrink tumors. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries.
Strategic signal
In January 2025, MetaboCure was featured in an article by Haaretz, highlighting its mission to restore life to cancer cachexia patients. This media attention underscores the company's commitment to addressing a critical unmet medical need and signals growing recognition of its innovative approach to treating a severe complication of cancer.
Log in to access full profile ›Company Intelligence Q&A
- What is MetaboCure's primary focus?
- MetaboCure is a biopharmaceutical company focused on developing novel therapies for cancer cachexia and other metabolic complications, aiming to restore patients’ strength and improve clinical outcomes.
- Who is the CEO and Co-founder of MetaboCure?
- Ronen Sarusi is the Co-founder and CEO of MetaboCure.
- What is Nuforal?
- Nuforal is MetaboCure's HNF4α mRNA/LNP-based drug, currently under development for the treatment of cancer cachexia. It aims to restore HNF4α levels in the liver to reverse disease symptoms.
- When was MetaboCure founded?
- MetaboCure was founded in July 2024.
- Has MetaboCure received any grants?
- In December 2024, MetaboCure secured a grant from the Israel Innovation Authority.